Linear Diagnostics

Birmingham, United Kingdom Founded: 2011 • Age: 15 yrs
Molecular diagnostic tests for sexually transmitted infections are developed.
Annual revenue - Latest available
Total funding $4.1M 4 rounds
Employees 4 Tracked headcount
Investors 7 Known backers
Products 2 Services tracked
Competitors 11 Brand Intelligence

About Linear Diagnostics

Linear Diagnostics is a company based in Birmingham (United Kingdom) founded in 2011 by Matthew Hicks. Linear Diagnostics has raised $4.08 million across 4 funding rounds from investors including Abingdon Health, British Business Bank and The University Of Birmingham. The company has 4 employees as of January 31, 2022. Linear Diagnostics offers products and services including Linear Dichroism Technology and EXPAR System. Linear Diagnostics operates in a competitive market with competitors including Inflammatix, Karius, MeMed, Visby Medical and GenMark Diagnostics, among others.

  • Headquarter Birmingham, United Kingdom
  • Employees 4 as on 31 Jan, 2022
  • Founders Matthew Hicks
  • Stage Minicorn
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Linear Diagnostics Limited
  • Date of Incorporation 29 Mar, 2011
  • Jurisdiction NOTTINGHAM, ENGLAND
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $4.08 M (USD)

    in 4 rounds

  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    4

    as on Jan 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Linear Diagnostics

Linear Diagnostics offers a comprehensive portfolio of products and services, including Linear Dichroism Technology and EXPAR System.

Product name locked
Category locked
Primary

Enables rapid and accurate detection of sexually transmitted infections at point of care.

Product name locked
Category locked
Locked

Facilitates quick testing for multiple infectious diseases in under 15 minutes.

People of Linear Diagnostics

Headcount 1-10
Employee Profiles 3
Board Members and Advisors 2
Employee Profiles
People
Jean-Louis Duprey
Head Of Research And Development
People
Brendan Farrell
Chairman & CEO
People
Richard Marlow
CFO

Unlock access to complete

Board Members and Advisors
people
David Coleman
Non-Executive Director
people
Robert Passas
Non-Executive Director

Unlock access to complete

Funding Insights of Linear Diagnostics

Linear Diagnostics has successfully raised a total of $4.08M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Linear Diagnostics

Linear Diagnostics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Abingdon Health, British Business Bank and The University Of Birmingham.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early-stage UK companies are invested in by Midven.
Locked Locked Locked
Investment funding is provided to support Midlands SMEs growth.
Locked Locked Locked
Early-stage innovations are funded by UKI2S across key sectors.
Locked Locked Locked
Premium access

Investor details for Linear Diagnostics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Linear Diagnostics

Investments
Premium access

Investment portfolio details for Linear Diagnostics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Linear Diagnostics

Premium access

Detailed financials for Linear Diagnostics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Linear Diagnostics Comparisons

Linear Diagnostics Primary company
Description
Molecular diagnostic tests for sexually transmitted infectio...
Location
Birmingham, United Kingdom
Founded Year
2011
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
4
As of 2022
Premium access

Peer comparison for Linear Diagnostics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Linear Diagnostics

Linear Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Karius, MeMed, Visby Medical and GenMark Diagnostics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Provider of diagnostic solutions for systemic infections
Locked Locked Locked
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
Locked Locked Locked
Provider of machine learning based diagnostic solutions for infectious diseases
Locked Locked Locked
Portable PCR diagnostics for infectious diseases are developed.
Locked Locked Locked
Instruments and test panels for multiplexed molecular diagnostics are provided.
Locked Locked Locked
Diagnostic technologies for infectious, cancer, and neurological diseases are developed.
Premium access

Detailed competitors of Linear Diagnostics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Linear Diagnostics

Premium access

Complete news archive for Linear Diagnostics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Linear Diagnostics

Linear Diagnostics was founded in 2011 and raised its 1st funding round 6 years after it was founded.

Linear Diagnostics is headquartered in Birmingham, United Kingdom. It is registered at Birmingham, England, United Kingdom.

Brendan Farrell is the current CEO of Linear Diagnostics.

Linear Diagnostics is a funded company, having raised a total of $4.08M across 4 funding rounds to date.

As of Jan 31, 2022, the latest employee count at Linear Diagnostics is 4.

Linear Diagnostics was founded in 2011 in Birmingham, United Kingdom, within the biotechnology sector. Molecular diagnostic tests for sexually transmitted infections are developed, focusing on Chlamydia trachomatis and Neisseria gonorrhoeae. An optical system that integrates linear dichroism with disposable cartridges and instruments is utilized. Gene sequences are detected through this dual-test approach, supporting clinical diagnostics in the medical field.

Linear Diagnostics's top competitors include Visby Medical, Inflammatix and MeMed.

Linear Diagnostics offers Linear Dichroism Technology and EXPAR System.

Linear Diagnostics has 7 investors. Key investors include Abingdon Health, British Business Bank, The University Of Birmingham, Future Planet Capital Regional, and NIHR.

The valuation of Linear Diagnostics is $2.61M as of Sep 2019.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available